What ChondroFiller costs in the UK

An injectable collagen scaffold used to treat focal cartilage defects in joints including the knee, hip, and shoulder, ChondroFiller is available in the UK at three published price tiers determined by how much product the defect requires:

• One box — £3,000
• Two boxes — £5,500
• Three boxes — £8,000

Each figure is all-inclusive: consultation, pre-procedure imaging review, real-time ultrasound guidance, the ChondroFiller implant, IV antibiotic cover, and a six-week follow-up appointment are all within the published price, with no additional charges on the day of treatment. The published figure is the total financial commitment — not a starting point for add-ons.

For most patients presenting with a single focal defect, one box is sufficient, placing the majority at the £3,000 entry point. Larger or multi-compartment joints such as the hip or shoulder carry a broader indicative range of approximately £6,500–£9,500+; this is less uniformly confirmed than the knee-focused tiers and should be treated as approximate until a personalised quote has been obtained following an imaging review.

These are guide costs confirmed by the treating clinic — not rough estimates — across multiple independent UK providers.

What determines your specific quote

Before any quote can be confirmed, the defect has to be measured. Box count — the single variable that determines which price tier applies — is set by the size and extent of the cartilage damage visible on imaging. A clinic that quotes without first reviewing the patient's MRI is working without the information the decision actually requires.

Defect geometry is not always predictable from symptoms alone: a larger lesion or damage across more than one compartment may require two or three boxes, while confined focal damage typically needs one. The pre-procedure imaging review is therefore a clinical step, not an administrative one.

At MSK Doctors, this assessment is supported by onMRI™, the group's AI-driven imaging analysis tool, which helps the consulting team characterise the defect before a treatment plan — and a final price — is agreed. Patients attending for a first consultation should bring any existing MRI scans; where no recent imaging is available, the team can arrange this in advance.

Once the review is complete, the quote is fixed. There are no upward revisions on the day of the procedure.

Why ChondroFiller is priced where it is

The cost reflects the nature of the product itself rather than the clinical time involved in delivering it.

ChondroFiller is manufactured by Meidrix Biomedicals GmbH in Germany and holds Class III CE certification — the highest regulatory tier for CE-marked medical devices, applied to implants where malfunction or failure carries a significant patient risk. That classification means the product passes through a substantially more demanding approval and supply chain than standard injectables such as hyaluronic acid or corticosteroid.

Critically, each box is procured on an individual patient-prescription basis. Nothing sits in a clinic stock room waiting for the next appointment; the product is sourced specifically for a named patient, which adds real per-patient regulatory and logistics costs to every procedure. This is a supply-chain reality, not a margin driver.

The procedure itself is comparatively lean. ChondroFiller is placed under real-time ultrasound guidance in an outpatient setting — approximately 30 to 45 minutes, no general anaesthetic, no theatre admission, same-day discharge. The clinical overheads of the appointment are modest. What the price reflects is the device.

For that reason, comparing it to a routine intra-articular injection is not a useful frame. The relevant comparison is other cartilage repair pathways — and on that basis the cost picture looks rather different.

NHS funding, private insurance, and self-pay

ChondroFiller is not available on the NHS; private treatment is the only pathway.

Private medical insurance is worth checking before assuming a self-pay position. The procedure is recognised under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500, and claims using both codes have been approved in practice — most frequently with Bupa, Aviva, and WPA — as of October 2025. How commonly approvals occur is not publicly quantified, but the codes exist precisely to give patients a documented basis on which to make the request. The practical step is to contact your insurer directly, quote both codes, and obtain written pre-authorisation before booking. A verbal indication is not sufficient. Bupa and AXA do not include ChondroFiller under routine benefit schedules, so written confirmation from your specific policy is the only reliable basis on which to proceed.

For patients without applicable cover, self-funding is the standard pathway. The all-inclusive pricing structure means the total commitment is established before the procedure date, with no additional charges on the day.

MSK Doctors accepts self-funding patients directly, without a GP referral and without NHS-style waiting times.

ChondroFiller cost versus surgical cartilage repair

Surgical cartilage repair gives a useful financial reference point for patients weighing their options. Keyhole scaffold-based procedures such as AMIC — performed under general anaesthetic and requiring theatre admission — typically cost between £9,800 and £14,000 at UK private clinics, with non-knee joints carrying a further uplift. Autologous chondrocyte implantation (ACI or MACI), the two-stage cell-based procedure recommended by NICE and available on the NHS in qualifying cases, costs approximately £16,000 per patient privately.

Against those figures, ChondroFiller's £3,000–£8,000 three-tier range represents a meaningful difference in financial commitment — broadly half the entry cost of AMIC/scaffold surgery, and well below the ACI/MACI range.

The cost gap sits alongside a difference in risk profile. Published data indicate a complaint rate of approximately 0% for the ultrasound-guided injection pathway, compared with complication rates of up to 17% reported in MACI surgical series. On functional outcomes, published evidence shows IKDC score improvements of approximately 30 points in knee cases — figures that are clinically competitive with early surgical series, though individual results vary.

These comparisons are intended as financial orientation rather than a clinical recommendation. Whether ChondroFiller is appropriate depends on defect size, joint location, and the consultant's assessment of the imaging — cost is one consideration, not the determining one.

Getting a personalised ChondroFiller quote at MSK Doctors

Taking the pricing structure as a whole, ChondroFiller occupies a defined space in the cartilage treatment landscape: a CE-marked injectable scaffold priced below surgical alternatives, with a fixed all-inclusive cost that can only be confirmed once imaging establishes the box count. For the majority of patients presenting with a single focal defect, that means a £3,000 commitment — known before the procedure date, with no additions on the day.

MSK Doctors delivers ChondroFiller as an ultrasound-guided outpatient injection at its Lincolnshire clinics in Sleaford (NG34) and Grantham (NG31), both accessible to patients across the wider non-London catchment. Patients with a recent MRI can bring it to the initial consultation; those without recent imaging can use the Open MRI at the Sleaford Regeneration Hub, where a scan and imaging-based quote can be completed without needing to arrange scans elsewhere first. London-based patients can access ChondroFiller through the London Cartilage Clinic, the group's London arm.

Appointments can be booked directly at mskdoctors.com, without a referral.